Crossref
Use of the JAK1/JAK2 inhibitor ruxolitinib in the treatment of patients with myelofibrosis
The Journal of Community and Supportive Oncology · 2013
DOI: 10.12788/j.cmonc.0054 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Community and Supportive Oncology, 2013. Verfasst von Hagop Kantarjian und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Kantarjian, H., Komrokji, R., Gotlib, J., Winton, E., & Mesa, R. (2013). Use of the JAK1/JAK2 inhibitor ruxolitinib in the treatment of patients with myelofibrosis. The Journal of Community and Supportive Oncology. https://doi.org/10.12788/j.cmonc.0054
Vancouver
Kantarjian H, Komrokji R, Gotlib J, Winton E, Mesa R. Use of the JAK1/JAK2 inhibitor ruxolitinib in the treatment of patients with myelofibrosis. The Journal of Community and Supportive Oncology. 2013. doi:10.12788/j.cmonc.0054
BibTeX
@article{Kantarjian2013,
author = {Kantarjian, Hagop and Komrokji, Rami and Gotlib, Jason and Winton, Elliott and Mesa, Ruben},
title = {Use of the JAK1/JAK2 inhibitor ruxolitinib in the treatment of patients with myelofibrosis},
journal = {The Journal of Community and Supportive Oncology},
year = {2013},
doi = {10.12788/j.cmonc.0054}
}
EUVIMED